Use of adjuvant EGFR tyrosine kinase inhibitors in early stage EGFR-mutant non-small cell lung cancer: is the evidence strong enough?

J Thorac Dis. 2020 Sep;12(9):5042-5045. doi: 10.21037/jtd-20-1817.
No abstract available

Publication types

  • Editorial
  • Comment